Single-use once again growth engine for Sartorius

By Staff Reporter

- Last updated on GMT

Image: iStock/Melpomenem
Image: iStock/Melpomenem

Related tags: Bioprocess solutions division, Marketing

Sartorius reported a 22% year-on-year growth in sales in its bioprocessing division, driven by continued demand for single-use systems.

For the full year 2016, the Sartorius Group has reported total sales of €1.3bn ($1.4bn), with the company’s Bioprocess Solutions Division – described by the firm as “the growth engine in the reporting year yet again”​ – contributing €975m.

The division incorporates the firm’s portfolio of disposable upstream and downstream biomanufacturing equipment and consumables, and the 22.1% growth on 2015’s results refelects industry’s continued demand for single-use technologies.

“Our Bioprocess Solutions Division is continuing to expand strongly,”​ said CEO Joachim Kreuzburg.

“As a supplier for the biopharmaceutical industry, the division addresses a very dynamic market and is additionally gaining market share in the important North American market.”

While it was thought Europe had initially led the way in embracing single-use technologies, Sartorius reported in January 2015​ that the US had caught up. Since then the firm has continued to report double-digit quarterly growth in the business unit.

According to the firm, 2016 sales were split geographically with the EMEA representing 44% of the firm’s revenues, while the Americas made up 34%, and Asia-Pacific represented 22%.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars